Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCSK9 mAb biosimilar
- Development stage
- Preclinical
- Lead developer
- Saya Bio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
PCSK9 mAb biosimilar is a monoclonal antibody biosimilar under development by Saya Bio. It is designed to target and inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that plays a critical role in cholesterol homeostasis by regulating the expression of low-density lipoprotein (LDL) receptors on the surface of hepatocytes [ADDITIONAL CONTEXT]. By binding to PCSK9, the antibody prevents it from degrading LDL receptors, thereby preserving receptor activity and increasing the clearance of LDL cholesterol from the bloodstream [ADDITIONAL CONTEXT]. The therapeutic candidate is currently in the cell line development stage of preclinical research.
- Other names
- Biosimilar de mAb anti-PCSK9
02
Targets
LDLR (Low-density lipoprotein receptor)PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on PCSK9 mAb biosimilar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PCSK9 mAb biosimilar.